Jan

10

2024

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...

Jan

09

2024

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...

Dec

20

2023

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...

Dec

14

2023

Vid extra bolagsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 14 december 2023 fattades följande beslut. ...

Dec

14

2023

Vid årsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 14 december 2023 fattades de beslut som beskrivs ned...

Dec

13

2023

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...

Dec

11

2023

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...

Dec

06

2023

Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, shares an updat...

Nov

29

2023

Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cance...

Nov

27

2023

Aktieägarna i Hamlet BioPharma AB (”Bolaget”), org.nr 556568-8958, kallas härmed till extra bolagsstämma torsdagen den 14 december 2023 klockan 16:30 ...